1. Motivated to quit smoking within 1 month from baseline (= ready to quit);
2. Not able to speak, read and write Dutch;
3. Contra-indication for the use of all forms of NRT;
4. Serious psychiatric morbidity (not only depressive symptoms);
5. Pregnancy.

- mec approval received

yes

- multicenter trial

no

- randomised

yes

- masking/blinding

None

- control

Active

- group

Parallel

- Type

2 or more arms, randomized

- Studytype

intervention

- planned startdate

1-okt-2013

- planned closingdate

1-okt-2014

- Target number of participants

32

- Interventions

Participants of the REDUQ II study receive one of the two (experimental and control) smoking reduction treatments of the REDUQ study (see NTR2227).

The REDUQ II study is an addendum study to the REDUQ trial (see NTR2227) and concerns a monocentre randomized single case experimental design (SCED). The study will be conducted to examine the patterns and processes of cognitive and behavioural changes in patients with COPD receiving smoking reduction treatment, offered during the REDUQ trial. The objective is to a) gain insight into the nature of the psychological processes (including cognitive as well as behavioural changes) that participants experience during the first six months of the REDUQ trial, and b) assess whether these processes are casually related to smoking cessation (attempts); and to what extent components of both interventions (intervention and control) i.e., reduction techniques, use of Nicotine Replacement Therapy (NRT), contribute to successful smoking reduction and quitting.